ORMP, US68403P2039

Oramed officer proposes USD 140,100 sale of Oramed Pharmaceuticals stock

Published on 10/02/2026 at 12:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The filing covers 30,000 shares under a March 30, 2026 trading plan. Oramed Pharmaceuticals stock costs EUR 3.99 on October 2, 2026 versus EUR 3.98.

ORMP, US68403P2039, Illustration mit AI erstellt.

Oramed Pharmaceuticals (ISIN US68403P2039) officer Joshua Hexter filed a proposed sale of 30,000 common shares valued at USD 140,100 for October 1, 2026, according to StockTitan. The filing says the transaction falls under a Rule 10b5-1 trading plan adopted on March 30, 2026. For investors, the key detail is the pre-arranged nature of the plan rather than a newly announced corporate financing.

ORMP was trading at EUR 3.99 at Lang & Schwarz on October 2, 2026 at 12:02 p.m. CEST, plus 0.25 percent versus the prior close of EUR 3.98 on October 1, 2026.

Annual meeting expands share plan

Oramed's latest formal corporate action came from its September 15, 2026 annual meeting. The company re-elected six directors, approved executive compensation and authorized 3,000,000 additional shares for its 2019 stock incentive plan, lifting the total authorization to 12,500,000 shares, according to the SEC filing.

The vote also set a three-year cycle for future advisory votes on executive compensation. The incentive-plan amendment passed with 11,336,951 votes for and 6,080,695 against, giving the capital-allocation decision a clear numerical split while increasing potential share authorization.

Second-quarter earnings add a valuation anchor

Oramed reported USD 78.16 million of net income and diluted earnings per share of USD 1.84 for the second quarter of 2026. CNN said second-quarter net income increased 104.01 percent from the prior quarter and 61.50 percent year over year, making the earnings figure the main fundamental comparison for the stock.

The finance profile places Oramed in healthcare biotechnology, with 13 full-time employees and a focus on orally delivered therapeutic proteins. The small operating base and the large reported net-income figure make the quality and repeatability of earnings an important issue for interpreting the headline result.

Nasdaq quote and next reporting date

On Nasdaq, ORMP was last at USD 4.48 on October 1, 2026 at 4:00 p.m. ET, while its 52-week range was USD 2.09 to USD 5.47. Investing.com lists November 16, 2026 as Oramed's next earnings date and identifies Nasdaq as the primary U.S. listing.

At Lang & Schwarz, the intraday euro quote stood at EUR 3.99 on October 2, 2026 at 12:02 p.m. CEST, up 0.25 percent against the EUR 3.98 prior close. The primary Nasdaq quote and the German euro indication reflect different venues and currencies.